Vascular endothelial cells produce nitric oxide (NO), which contributes to the regulation of blood pressure and regional blood flow. Endothelial nitric oxide synthase (eNOS) gene polymorphisms are associated with coronary artery disease, but their linkage with primary hypertension is controversial. A total of 103 individuals with primary hypertension and 104 normotensive control subjects were studied in Singapore. The specific genotypes for G894T missense variant in exon 7, variable number tandem repeats (VNTR) in intron 4 (eNOS 4A/B/C) and TÀ786C in the promoter were isolated using allele-specific gene amplification and restriction fragment length polymorphism to examine the association of genotype and allelic frequency in both groups. Logistic regression analysis was also used to detect the association between genotypes and hypertension. Five genotypes of intron 4 VNTR (AA, AB, BB, AC and BC) were observed. Intron 4 B/B genotype was significantly associated with the hypertension group (P ¼ 0.035), but disequilibrium of G894T and TÀ786C was absent between the two groups (P ¼ 0.419 and P ¼ 0.227), respectively. The overall distribution of allelic frequency differed significantly between the two groups, with four-repeat allele (4A) of intron 4 more frequent in the normotensive group than the hypertensive group (P ¼ 0.019). Logistic regression analysis showed that intron 4 B/B genotype was significantly associated with systolic blood pressure of individuals with body mass index greater than 25 kg/m 2 (P ¼ 0.04). In conclusion, the eNOS 4 B/B genotype is a genetic susceptibility factor for primary hypertension in a Singapore population.
Introduction
The pathogenesis of hypertension is multifactorial and involves both genetic and environmental mechanisms. Nitric oxide (NO) synthesis by the vascular endothelium is important for the regulation of vasodilator tone and control of blood pressure in humans. 1 Accumulating evidence suggests that an alteration in NO metabolism contributes to the pathogenesis of hypertension. [2] [3] [4] In patients with primary hypertension, basal whole-body NO production is diminished and plasma NO levels inversely correlate with systolic and diastolic blood pressures. 5, 6 Endothelial nitric oxide synthase (eNOS) catalyses the production of NO from L-arginine in vascular endothelial cells 7 and polymorphisms in eNOS gene might be associated with impaired NO release. The G-to-T conversion at nucleotide 894 (G894T) in exon 7 of eNOS gene introduces an aspartate in place of a glutamate residue (Glu298Asp) and is associated with increased risk of myocardial infarction, 8 hypertension 9,10 and coronary artery spasm. 11 Another variant of eNOS promoter region (TÀ786C) with cytosine replacing thymidine at nucleotide À786 is reported to have increased risk of hypertension 12 and coronary spasm. 13 Variable number of tandem repeats (VNTR) of intron 4 has been shown to have a significant association with primary hypertension, 14 isolated lacunar infarction 15 and a smoking-dependent risk of coronary artery disease. 16 Two alleles of intron 4 VNTR have been reported: bigger allele 4B has five tandem 27 bp repeats and smaller allele 4A has four repeats. 16 The consensus sequence GAAGTCTA GACCTGCTGCA/GGGGGTGAG in which the first three repeats have A and last two repeats have G at the 19th base has been defined. 17 A new polymorphism consisting of an additional 27 bp repeat (4C) was found at very low frequency in a Caucasian population without significant association with coronary artery disease or hypertension. 18 Although the precise molecular effects of these polymorphisms have not been elucidated, there is biochemical evidence of reduced eNOS protein expression and enzymatic activity associated with eNOS intron 4 VNTR and TÀ786C polymorphism variants. 13, 19 In this study, we investigated G894T, TÀ786C and intron 4 VNTR polymorphisms association with hypertensive subjects attending the National Heart Centre, Singapore.
Methods

Study population
A total of 103 patients (68 male, 35 female) with primary hypertension were recruited from the National Heart Centre, Singapore according to the following criteria: (1) patient age more than 20 years, (2) onset of hypertension before 60 years of age, (3) established hypertension defined either as longterm treatment of the disease or in those previously untreated with systolic blood pressure 4140 mm Hg or diastolic blood pressure 490 mm Hg on two consecutive visits and (4) absence of secondary forms of hypertension including chronic renal diseases as determined through extensive workup. A group of 104 normotensive control subjects (74 male, 30 female) were also recruited from the same clinics according to the following criteria: (1) subject age more than 20 years, (2) absence of hypertension and antihypertensive treatment in the medical history and (3) systolic/diastolic pressure o140/ 90 mm Hg. 9 The study was approved by Singapore General Hospital Ethics Review Committee and informed consent was obtained from each subject at recruitment. Each patient's medical history was obtained using a standardized questionnaire and face-to-face interview. We recorded medical history of hypertension, diabetes, dyslipidaemia, kidney diseases and current medications, in particular, antihypertensive, antidiabetic and lipid-lowering agents. Subjects with history of diabetes or receiving antidiabetic medications were considered to be diabetic. Subjects were deemed dyslipidaemia when their total cholesterol concentration was X5.17 mmol/l or triglyceride concentration 1.68 mmol/l or they were receiving lipid-lowering drugs. A complete physical examination was performed including measurement of supine systolic and diastolic blood pressure.
Biochemical assays
Plasma concentrations of total cholesterol, lowdensity lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides and serum concentrations of creatinine and uric acid were measured using standard methods at the Clinical Laboratory, Singapore General Hospital. Concentrations of NO product, nitrite, were determined without fasting, by using Griess reagent kit (Molecular Probes, Eugene, OR, USA) following the manufacturer's instruction. The Griess method converts nitrate to nitrite, hence the current measurement represents the sum of nitrite and nitrate in plasma.
Genotype assays
Genomic DNA was extracted from whole blood using the QIAamp DNA blood kit (Qiagen, Valencia, CA, USA) following the manufacturer's instruction. Genotyping of each polymorphism was performed by amplification from 50 to 100 ng of genomic DNA. The eNOS polymorphisms studied were G894T, TÀ786C and intron 4 VNTR. The primer sequences used for these polymorphisms are listed in Table 1 , and polymerase chain reaction and restriction fragment length polymorphism conditions have been described previously. 12, 16, 20 The eNOS alleles A (four repeats), B (five repeats) and C (six repeats) of intron 4 VNTR were identified as fragments corresponding to 393, 420 and 447 bp, respectively, on NuSieve 3:1 agarose gel (Cambrex Bio Science, Rockland, ME, USA) as described. 21 In addition, the 27 bp repeat elements were verified by DNA sequencing.
Analysis of clinical parameters, genotypes and allele frequencies All values for clinical parameters are expressed as mean7s.e. Differences in the frequencies of the following quantitative variables were tested using unpaired, two-tailed Student's t-test: age, systolic blood pressure, diastolic blood pressure, body mass index (BMI), plasma total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, glucose, urea, creatinine and nitrite. Gender ratios were tested by w 2 test with 1 df. Values of Po0.05 were considered statistically significant. The strength of association with the presence of diabetes and dyslipidaemia was estimated with odds ratio and 95% confidence intervals (CIs).
For each allelic marker, allele frequencies were calculated from the genotypes in the hypertensive and normotensive groups. Deviation from HardyWeinberg equilibrium was assessed using w 2 test with 1 df. Hardy-Weinberg equilibrium for intron 4 multiple alleles was examined following the algorithm described by Guo and Thompson. 22 Differences in genotype distribution and allele frequencies between hypertensive and control subjects and genotype distribution pattern of diabetes, dyslipidaemia and their control subjects among hypertensive and control groups were tested using Fisher's exact test. 9 Logistic regression analysis was also used to detect the association between genotypes and hypertension. Primary hypertension was regarded as the dependent variable, and genotype, gender, age, BMI and concentration of plasma total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, glucose, nitrite urea and creatinine were entered as independent variables.
Results
Subject characteristics
The clinical characteristics of the 103 hypertensive and 104 normotensive subjects are summarized in Table 2 . Both systolic and diastolic blood pressures in the hypertensive group were significantly higher than in the control group (both P ¼ 0.0001). BMI of the hypertensive group was also significantly higher than the control group (P ¼ 0.033). Plasma nitrite concentrations of the hypertensive group was significantly lower than the control group (P ¼ 0.008). Diabetes and dyslipidaemia were more frequent in subjects with primary hypertension (odds ratio 2.4, 95% CI 1.22-4.88; P ¼ 0.01; odds ratio 2.2, 95% CI 1.25-3.85; P ¼ 0.006), respectively. Both Student's t-test and logistic regression analysis showed no significant differences between the two groups with respect to total serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, urea and creatinine.
Genotype distribution
Three types of polymorphism in the eNOS gene, G894T, TÀ786C and intron 4 VNTR, were analysed in hypertensive and normotensive subjects ( Table 3) . The genotype frequencies of all three polymorphisms in both groups satisfied Hardy-Weinberg equilibrium.
In our study, five genotypes of intron 4 VNTR (BB, BA, AA, BC and AC) were observed ( Figure 1 ) and genotype frequencies were 0.65, 0.29, 0.029, 0.009 and 0.009 for normotensive subjects and 0.78, 0.17, 0.009, 0.029 and 0.009 for hypertensive subjects, respectively. Those who were heterozygous and those who were homozygous for the less frequent alleles (the A and C alleles) were pooled together for analysis because of the small number of individuals with homozygous alleles. Our results showed a significant association of BB genotype and the hypertensive group (BB versus AA, BA, BC and AC) (odds ratio 1.8, 95% CI 0.9-3.4; P ¼ 0.035). The BB genotype frequency in our control normotensive subjects was similar to a study of Caucasians (0.69), 18 but lower than a study from Japan (0.925) 14 and higher than an African-American study (0.536). 21 Our results also showed a significant increase in the 4A allelic frequency of the intron 4 VNTR variant in the control normotensive subjects (A versus B and C); allele frequencies of B, A and C were 0.0.81, 0.18, 0.009 and 0.88, 0.10 and 0.019 for control and hypertensive groups, respectively (P ¼ 0.019).
G894T and TÀ786C variants of eNOS were also studied. G894T genotype frequencies for G/G, G/T and T/T of G894T were 0.78, 0.20 and 0.009 for normotensive subjects and 0.77, 0.19 and 0.04 for hypertensive subjects. The genotype distribution of this variant was similar to a previous study of Singaporean Chinese with coronary artery disease. 23 Our study showed no significant effect of this genotype on the incidence of hypertension (P ¼ 0.419) and no significant increase in the G or T allelic frequency in the hypertensive subjects compared with the control group (P ¼ 0.263). The genotype distribution and allelic frequency of TÀ786C variant was similar between hypertensive and control subjects (P ¼ 0.227 and P ¼ 0.207, respectively).
Three polymorphisms of eNOS gene were also analysed in diabetes, dyslipidaemia and their control subjects among hypertensive and normotensive subjects (Table 4) . G/T þ T/T genotypes of exon 7 G894T were significantly higher in diabetes than their control non-diabetes among hypertensive subjects (P ¼ 0.038). However, G894T variant showed no significant association between diabetes and their control non-diabetes among normotensive subjects (P ¼ 0.122). Moreover, genotype frequencies of intron 4A/B/C and TÀ786C variant were similar between diabetes and non-diabetes among both hypertensive and normotensive subjects. Furthermore, our study demonstrated that no significant effect of all three genotypes (G894T, intron 4A/B/C and TÀ786C) on the incidence of dyslipidaemia and their control non-dyslipidaemia among hypertensive subjects (P ¼ 0.243, P ¼ 0.512 and P ¼ 0.113), respectively, and nomotensive subjects (P ¼ 0.328, P ¼ 0.094 and P ¼ 0.486), respectively. Primary hypertension in Singaporeans: eNOS genotype association KT Moe et al.
Logistic regression analysis revealed the significant association of intron 4BB genotype with systolic blood pressure in our study population with BMI greater than 25 kg/m 2 (P ¼ 0.04) ( Table 5) .
Discussion
This is the first report showing a significant association of eNOS gene intron 4 VNTR genotype BB and primary hypertension in Singapore (Table 3) . We also found a significant increase in allelic frequency of intron 4A in normotensive subjects.
The intron 4A allele was a protective factor against the development of acute coronary syndrome (ACS) and the GG genotype of G894T had an additive beneficial effect on the intron 4A, although by itself was not found to be a significant protective factor against ACS. 24 Intron 4A variant was also shown to be protective against cerebral small-vessel diseases with a confined effect to isolated lacunar infarction and suggested that the protective effect of the intron 4A could be mediated through changes in the eNOS promoter activity and increased NO levels. 15 Our results also showed the significant association of intron 4BB genotype with primary 
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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hypertension and the protective effect of intron 4A allele against the disease. A significant excess of homozygotes for the rare intron 4A allele in patients with severely stenosed arteries in Australian subjects was reported, but the study did not provide an association with hypertension. 16 However, a study from Japanese subjects showed the association of intron 4A allele with primary hypertension.
14 Our divergent findings might reflect differences in genetic background, because the frequency of eNOS polymorphisms has been shown to vary markedly among different ethnic groups 25 or differences in environmental exposure, which has been shown to modify the influence of eNOS variants on disease risk. 16 There are a number of possible explanations for the association of intron 4 VNTR BB and primary hypertension. The intron 4 locus could act as a marker for another functional polymorphism in linkage disequilibrium. 15 Another possibility is that intron 4A allele has intrinsic functional significance, which can be justified with plasma NO metabolites concentration. Although we did not detect a positive linear relationship of the 4A allele with plasma NO metabolites in our study, we found significantly higher levels of plasma NO metabolites in control normotensive subjects who had significantly increased 4A allele. Our finding is comparable with a report that showed significant high levels of NO metabolites among white subjects with 4AA genotype. 26 Furthermore, a study from Korea also elaborated the significant association of 4A allele and plasma NO metabolite concentrations. 27 Moreover, a propensity of high blood urea and creatinine level in hypertensive group in the present study also elucidated lower plasma nitrite level in these subjects. Intron 4 VNTR has been suggested to function as a transcriptional or translational regulator that might modify protein function. 28 Several other reports have suggested a combined protective effect of intron 4 and G894T or TÀ786C variants. 15, 24, 29 In our study, we observed a significant association of intron 4BB genotype with systolic blood pressure among subjects with BMI greater than 25 kg/m 2 . BMI is known to have an effect on blood pressure and atherosclerosis and insulin sensitivity. [30] [31] [32] [33] The interaction between L/F polymorphism of E-selectin gene and BMI on blood pressure has been reported. 34 Another report showed the significant association of eNOS gene variant TÀ786C polymorphism in men with hypercholesterolaemia and obesity in Caucasians. 35 Our study suggests that genetic susceptibility for hypertension may increase with individuals with BMI greater than 25 kg/m 2 and intron 4BB genotype. Furthermore, subjects with high BMI (30-45 kg/m 2 ) has been reported to have significantly lower insulin sensitivity, as measured by the homeostasis model assessment of insulin resistance (HOMA IR), and serum adiponectin than non-obese subjects (P ¼ 0.01). 33 In addition, subjects with high IR (above the median HOMA IR) showed significantly greater differences in blood pressure levels between non-carriers and carriers of the T894 allele. 36 These workers also reported that G894T genotype and IR also showed a combined effect on the prevalence of parental hypertension, with non-carriers versus carriers in the high IR group. Our results demonstrated the significant association of higher BMI with hypertensive than normotensive subjects (P ¼ 0.033) and higher G/T þ T/T genotypes frequency with diabetes among hypertensive subjects (P ¼ 0.038), suggesting that G894T variant of eNOS gene in conjunction with BMI may be one factor contributing to the predisposition to hypertension.
Several studies have shown an association between the G894T variant and hypertension. However, varied results have been obtained in studies of different populations: the G allele was associated with hypertension in Caucasians 37 and the T allele was associated with hypertension in Japanese. 9, 10 However, the G894T polymorphism was not associated with hypertension in other studies among Japanese 38 and Caucasians. 39 In our study, we did not detect any association of G894T and TÀ786C polymorphisms with hypertension, in accordance with a previous study of G894T polymorphism in Singapore patients with coronary artery disease. 23 Moreover, genotype frequencies of all three eNOS gene polymorphisms were similar between dyslipidaemia and non-dyslipidaemia among both hypertensive and normotensive subjects in our study, comparable to the previous report. 40 There are limitations for studies such as ours. We examined the distribution of polymorphisms in 104 control normotensive and 103 hypertensive subjects, which is not a large sample. However, to estimate a positive association in a complex polygenic disease requires X10 2 per group, 41 and our power estimates confirmed the capacity of our study to do this. Moreover, the genotype prevalences of the Published studies of association between the eNOS genotypes and cardiovascular diseases
What is known about this topic K Three major genetic polymorphisms of the eNOS gene have been reported as susceptibility genes in a number of cardiovascular diseases. 9, 10, 12, 14 K VNTR of intron 4 has been shown to have a significant association with primary hypertension in Japanese, 14 acute coronary syndrome in Koreans 24 and smoking-dependent risk of coronary artery disease in Australians.
polymorphisms in each group of our study were in Hardy-Weinberg equilibrium, which allows us to exclude the possibility of selection bias. Also, sample size was sufficiently large to study that allele prevalences of the control group were comparable with previous published data. 23 In conclusion, we demonstrated that eNOS gene intron 4BB genotype is significantly associated with primary hypertension in a Singapore population. Our data suggest that the intron 4BB genotype may be a genetic susceptibility factor of primary hypertension.
